Lucid Diagnostics, Inc (LUCD) Price to Earnings Ratio

Corporate emblem and logo of Lucid Diagnostics Inc (LUCD)

Lucid Diagnostics Inc. (LUCD) generates revenue from the diagnosis of precancerous esophageal pathologies by offering EsoGuard tests to gastroenterologists and individuals with GERD. New Medicare codes and the expansion of specialized center networks support business growth. The price history on GURU.Markets, where the indicator stands at -1.20, confirms the resilience of a business protected by FDA patents and the inclusion of its methodologies in official medical protocols.

LUCD Lucid Diagnostics: Price to Earnings Ratio in the range 08/22/2022 - 11/11/2026

Analytical breakdowns for Lucid Diagnostics Inc.

- price and consensus price forecast:
Stock Price luciddx.com|LUCD - Price Target Chart
- market capitalization details:
Market Value Lucid Diagnostics Inc.|LUCD - Real Price to Acquire Entire Company
- book capitalization information:
Net Asset Value per Share Lucid Diagnostics|LUCD - Company Book Value|Market Capitalization to Book Value luciddx.com|LUCD - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Lucid Diagnostics Inc.|LUCD - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Lucid Diagnostics, Inc|LUCD - Company Debts|Debt to Book Capitalization Ratio Lucid Diagnostics Inc.|LUCD - Company Long-Term Liabilities|Company Short-Term Debts Lucid Diagnostics|Quick Liquidity Indicator luciddx.com
- business earnings and investment ratios data:
LUCD - Net Profit|Company Profit Forecast Lucid Diagnostics Inc.|LUCD - P/E Multiple|Price to Future Earnings Ratio Lucid Diagnostics, Inc.|LUCD - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Lucid Diagnostics Inc.|LUCD - Operating profit EBITDA|Earnings per share for the last 12 months Lucid Diagnostics|LUCD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months luciddx.com|LUCD - Earnings growth in current year|Earnings growth forecast for next year Lucid Diagnostics Inc.
Comprehensive company analysis:luciddx.com
Manufactured product of Lucid Diagnostics Inc.

Lucid Diagnostics Inc. (LUCD) is transforming esophageal cancer diagnostics through its non-invasive EsoGuard test, which serves as a replacement for endoscopy. The P/E ratio quantifies the value of this technological advantage by comparing the market price of the stock with the net earnings per share. By analyzing the company's historical P/E levels, an investor can determine the extent of the premium paid for future earnings growth. Low values minimize the risk of a correction, yet they may signal market skepticism regarding the scalability of these innovations.

Competing companies

P/E Multiple agilent.com|Price to Earnings Ratio Quest Diagnostics Incorporated (DGX)|Price to Earnings Ratio ILMN (Illumina Inc)|Cologuard - Price to Earnings Ratio|Revvity Corp (RVTY) - Market Cap to Earnings|BIO - Price to Earnings Ratio|Business Payback Period anbio.com NNNN|SHC: P/E Multiple|QDEL - Business Payback Period|Price to Earnings Ratio OPKO Corp|caredx.com (CDNA) - Business Payback Period|Price to Earnings Ratio Maravai LifeSciences (MRVI)|Price to Earnings Ratio FLGT (fulgentgenetics.com)|Standard BioTools - Price to Earnings Ratio|P/E Multiple Cytek Biosciences Inc CTKB|OraSure Technologies Inc - P/E Multiple|Exagen Inc. (XGN) - Price to Earnings Ratio|MDXH: P/E Multiple|PRE - Business Payback Period|IMDX (Insight Molecular Diagnostics, Inc.) - P/E Multiple|Price to Earnings Multiple TRIB (Trinity Biotech Corp)|Price to Earnings Ratio PRPH (ProPhase)|AIMD (Ainos Corporation) - Company Value to Net Income|P/E Multiple CODX (Co-Diagnostics, Inc.)|HSCS: Price to Earnings Multiple|Biomerica - P/E Multiple|Business Payback Period Cardio Diagnostics CDIO|ONCO: P/E Multiple|Virax Biolabs Corp (VRAX) - P/E Multiple|BJDX (Bluejay Diagnostics) - P/E Multiple|AWH - Market Cap to Net Income Ratio|Price to Earnings Ratio Accelerate Diagnostics, Inc. (AXDX)|CENTOGENE - Price to Earnings Multiple|Price to Earnings Ratio Enzo Biochem ENZ|Fresh2 Group Ltd (FRES) - Market Cap to Earnings|GENE - Price to Earnings Ratio|Business Payback Period 23andme.com ME|PMD (Psychemedics Corporation) - Price to Earnings Ratio